The Effect of Antecedent Hypoglycaemia on Î²2-Adrenergic Sensitivity
Information source: Radboud University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes; Hypoglycemia Unawareness
Intervention: Hypoglycemia (Procedure)
Status: Active, not recruiting
Sponsored by: Radboud University
Official(s) and/or principal investigator(s):
Paul Smits, PhD, MD, Principal Investigator, Affiliation: Radboud University
Hypoglycaemia unawareness is a common complication in patients with type 1 diabetes and with
insulin-treated type 2 diabetes of long duration. The loss of autonomic symptoms to
hypoglycemia does not solely depend on loss of adrenaline responses. Differences in
sensitivity to catecholamines may also be involved.
Reconciling the data on β2-adrenergic receptor polymorphism to those on loss of β-adrenergic
sensitivity in diabetic patients with hypoglycemia unawareness, we hypothesize that
hypoglycemia unawareness is at least partly the result of desensitization of the
β2-adrenergic receptor and that patients who are homozygous for arginine at codon 16 are
particularly susceptible for this desensitization process, whereas patients who are
homozygous for glycine at codon 16 are resistant for desensitization.
1. To determine whether, and if so to what extent, antecedent hypoglycemia reduces
β2-adrenergic sensitivity in healthy subjects with Arg16 homozygosity.
2. To investigate whether or not healthy subjects with Gly16 homozygosity are resistant to
3. To confirm that antecedent hypoglycemia reduces the heart rate response to isoproterenol
and to assess to what extent this reduced response is mediated by impairments in
Official title: The Effect of Antecedent Hypoglycaemia on β2-Adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-Adrenergic Receptor
Study design: Diagnostic, Randomized, Single Blind, Placebo Control, Crossover Assignment
Minimum age: 18 Years.
Maximum age: 40 Years.
- Informed consent
- Homozygous for Arginine at codon 16 or homozygous Gly at codon 16
- No regular usage of medication other than oral contraceptives
- History of cerebrovascular, cardiovascular, or peripheral vascular disease
- Alcohol usage of more than 10 units per week
- Inability to abstain from xanthine-derivatives (coffee, tea, cola, chocolate, cacao)
or alcohol for 2 days
- BMI above 30 kg/m2
- Participation to any other trial in the preceding 3 months
- Ongoing disease of any kind
Locations and Contacts
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland 6500HB, Netherlands
Starting date: April 2005
Ending date: February 2007
Last updated: February 28, 2007